CREDIT AND GUARANTY AGREEMENT dated as of September 16, 2013 among K-V PHARMACEUTICAL COMPANY, as Borrower, CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, VARIOUS LENDERS, and LAW DEBENTURE TRUST COMPANY OF NEW YORK, as Agent $100,000,000 First Lien...Credit and Guaranty Agreement • September 23rd, 2013 • Kv Pharmaceutical Co /De/ • Pharmaceutical preparations
Contract Type FiledSeptember 23rd, 2013 Company IndustryThis CREDIT AND GUARANTY AGREEMENT, dated as of September 16, 2013, is entered into by and among K-V PHARMACEUTICAL COMPANY, a Delaware corporation (“Borrower”), CERTAIN SUBSIDIARIES OF BORROWER, as Guarantors, the Lenders party hereto from time to time, and LAW DEBENTURE TRUST COMPANY OF NEW YORK, as administrative agent and collateral agent (in such capacities, together with any successors and assigns, collectively, “Agent”).
STOCKHOLDERS’ AGREEMENT OFStockholders' Agreement • September 23rd, 2013 • Kv Pharmaceutical Co /De/ • Pharmaceutical preparations • New York
Contract Type FiledSeptember 23rd, 2013 Company Industry JurisdictionTHIS STOCKHOLDERS’ AGREEMENT, dated as of September 16, 2013 (this “Agreement”), by and among K-V Pharmaceutical Company, a Delaware corporation (the “Company”), each Investor, each Person who beneficially owns any shares of Common Stock as of the date hereof, each Person receiving any shares of Common Stock on the date hereof and each other Person who from time to time beneficially owns any shares of Common Stock and is deemed a party to this Agreement in accordance with the provisions herein and in the Certificate of Incorporation (collectively, the Investors and each such other Person, the “Holders,” and, individually, a “Holder”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 23rd, 2013 • Kv Pharmaceutical Co /De/ • Pharmaceutical preparations • New York
Contract Type FiledSeptember 23rd, 2013 Company Industry JurisdictionTHIS REGISTRATION RIGHTS AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is entered into as of September 16, 2013, by and among K-V Pharmaceutical Company, a Delaware corporation (the “Company”), and the persons identified on Schedule A hereto (each, a “Holder”).